Why CRDF Stock dropped -2.46% Today — RQD Quant Desk Flash

Per the Roarable RQD rating, CRDF scores 41/100 with a letter grade of D- and the verdict "Roarable Sell — Vulnerable Balance Sheet & Flow." The five pillars are:

• Fundamental Cash Engine: 5/20. Return on invested capital is -35% and FCF yield is 0%. For an investor, this indicates the business is not currently generating returns on the capital it deploys, so value would depend on future developments rather than present cash generation.
• Whale 13F Flow: 15/20. The rating cites institutional accumulation and options positioning. This is the strongest pillar, suggesting some institutional interest, though the source data does not itemize holders (see Analyst View section).
• Insider Conviction: 3/20. The rating cites SEC Form 4 and Congressional PTR cluster flow at a low score, which an investor should read as limited insider-side confidence signals.
• Macro Regime Fit: 11/20. Beta is 1.0 and the rating notes sector sensitivity. The stock moves in line with the broad market on this measure, with no defensive cushion indicated.
• Forensic Balance Sheet: 7/20. Altman Z-Score is 2.5, Piotroski F-Score is 1 of 9, and Debt/Equity is 0.5. The weak Piotroski reading points to poor financial-health signals across the nine tests.

Upside drivers in the data are limited to the pipeline and institutional interest; the valuation tradeoff is that a $70.9M market capitalization with negative operating margin (-60%) and negative ROIC leaves little earnings support for the current price. The rating's overall posture is cautious.

Per the SEC financials, operating losses are consistently large relative to revenue, and the operating margin is -60%. Net margin is -7.7% and gross margin is 0%. ROIC is -35%. Cash declined from $51.5M in FY 2024 to $17.5M in FY 2025, a reduction of $34.0M in one year. The Altman Z-Score is 2.5 and the Piotroski F-Score is 1/9, per the Roarable RQD rating. The Debt/Equity ratio is 0.5; the debt line itself is not available in source data.

Per the recent news feed, the following items are listed:

• Trial and management update (YELLOW): Reporting states that all trial patients still enrolled have received more than 18 months of treatment, and that the company named an interim medical chief.
• Earnings preview (YELLOW): A TradingView item references a Q3'26 EPS estimate of (0.14) USD.
• Q2 2026 earnings (RED, Risk Watch): An item describes a narrower-than-expected loss while advancing the clinical-stage pipeline.
• Share authorization (YELLOW): Holders approved doubling authorized common stock to 300 million shares. This is a potential dilution consideration.
• Price action (YELLOW): One report describes shares sliding 7.21% to $0.90 and testing a lower support zone; the current market data shows a price of 0.89 and a change of -2.2%.
• Forecast article (YELLOW): A StockInvest.us item discusses market action and institutional positioning.

The Butterfly supply-chain graph lists no links and no proprietary signals.

Per the Butterfly Supply-Chain Graph, the supply chain is listed as NONE, with no butterfly links. Upstream and downstream dependencies, sector correlations, and bottlenecks are not available in source data. The most relevant second-order consideration visible in the data is the approved increase in authorized shares to 300 million, which a prospective investor could track for dilution effects on per-share value given the $0.89 price and $70.9M market capitalization.

• What is the company's cash runway given cash of $17.5M at FY 2025 against FCF of -$38.0M?
• What is the debt balance behind the reported Debt/Equity of 0.5, and what are the maturities?
• What specific clinical programs drive the pipeline, and what are their timelines and milestones?
• What is the source and magnitude of the institutional accumulation cited in the whale-flow pillar?
• How will the approved increase to 300 million authorized shares affect outstanding shares and dilution?